(19)
(11) EP 1 810 970 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
21.03.2012 Bulletin 2012/12

(45) Mention of the grant of the patent:
12.05.2010 Bulletin 2010/19

(21) Application number: 07104074.5

(22) Date of filing: 24.09.2003
(51) International Patent Classification (IPC): 
C07D 403/04(2006.01)
C07D 285/10(2006.01)
C07D 241/20(2006.01)
C07D 213/74(2006.01)
A61P 29/00(2006.01)
C07D 401/04(2006.01)
C07D 237/20(2006.01)
C07D 239/42(2006.01)
A61K 31/496(2006.01)

(54)

Therapeutic piperazine compounds

Therapeutische Piperazinverbindungen

Composés thérapeutiques de pipérazine


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LV MK

(30) Priority: 24.09.2002 US 412847 P

(43) Date of publication of application:
25.07.2007 Bulletin 2007/30

(62) Application number of the earlier application in accordance with Art. 76 EPC:
03754883.1 / 1562936

(73) Proprietor: EURO-CELTIQUE S.A.
1653 Luxembourg (LU)

(72) Inventors:
  • Sun, Qun
    Princeton, NJ 08540 (US)
  • Zhou, Xiaoming
    Plainsboro, NJ 08536 (US)

(74) Representative: Hansen, Norbert 
Maiwald Patentanwalts GmbH Elisenhof Elisenstraße 3
80335 München
80335 München (DE)


(56) References cited: : 
WO-A-00/52001
WO-A-02/08221
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).